Skip Navigation

Annals of Oncology 2008 19(7):1211; doi:10.1093/annonc/mdn415
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

In this issue

The first 10% of the full text of this article appears below.


   Premenopausal endocrine-responsive early breast cancer
 
For endocrine-responsive breast cancer, the benefit of chemotherapy is due to a complex mixture of cytotoxic and endocrine mechanisms. The additional benefit of chemotherapy for premenopausal patients with endocrine-responsive breast cancer who receive combined endocrine treatment with ovarian function suppression/ablation and tamoxifen (or an aromatase inhibitor) remains an open question that prospective randomized clinical trials (RCTs) have been unsuccessful in answering, as diverging opinions regarding its efficacy result in some physicians recommending it while . . . [Full Text of this Article]


   XELOX in first-line treatment of metastatic colorectal cancer
 

   Autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
 

   Stopping trials early in oncology
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
M. M. Regan, O. Pagani, B. Walley, R. Torrisi, E. A. Perez, P. Francis, G. F. Fleming, K. N. Price, B. Thürlimann, R. Maibach, M. Castiglione-Gertsch, A. S. Coates, A. Goldhirsch, R. D. Gelber, and for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group
Ann Oncol 2008 19: 1231-1241. [Abstract] [Full Text]  

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
M. Borner, D. Koeberle, R. Von Moos, P. Saletti, D. Rauch, V. Hess, A. Trojan, D. Helbling, B. Pestalozzi, C. Caspar, T. Ruhstaller, A. Roth, A. Kappeler, D. Dietrich, D. Lanz, W. Mingrone, and for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Ann Oncol 2008 19: 1288-1292. [Abstract] [Full Text]  

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
B. Sirohi, D. Cunningham, R. Powles, F. Murphy, T. Arkenau, A. Norman, J. Oates, A. Wotherspoon, and A. Horwich
Ann Oncol 2008 19: 1312-1319. [Abstract] [Full Text]  

Stopping a trial early in oncology: for patients or for industry?
F. Trotta, G. Apolone, S. Garattini, and G. Tafuri
Ann Oncol 2008 19: 1347-1353. [Abstract] [Full Text]